Search results
Gene Prediction in Eukaryotes. Novel eukaryotic genomes can be analyzed by the self-training GeneMark-ES. The fungal mode of GeneMark-ES accounts for fungal-specific intron organization. GeneMark-ET integrates into GeneMark-ES information on mapped RNA-Seq reads.
GenMark has rebranded its rapid syndromic molecular diagnostic solution under the Roche cobas brand, with upgraded features based on customer input across all aspects of the workflow process.
As genetic surveillance of SARS-CoV-2 strains circulating globally continues to identify new variants and mutations that can potentially impact detection by nucleic acid-based testing methods, GenMark continues to monitor the evolution of SARS-CoV-2 variants and remains committed to providing laboratories with high-quality testing solutions ...
The amplified target DNA hybridizes to the capture probe and to a complementary ferrocene-labeled signal probe. Electrochemical analysis determines the presence or absence of targets using voltammetry. en The ePlex system is used to run multiplex microarray-based assays developed by GenMark.
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care.
Mar 15, 2021 · GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample. GenMark’s ePlex platform delivers rapid and actionable results so...
Mar 15, 2021 · Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
Mar 15, 2021 · COVID-19 diagnostic tests infectious disease mergers and acquisitions. Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen...
Mar 15, 2021 · Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday. Roche said it will launch a...
Mar 15, 2021 · Roche Holding AG, the Swiss pharmaceutical group that developed the first molecular test for COVID-19, has agreed to acquire the U.S.' GenMark Diagnostics Inc. in a $1.8 billion cash deal, boosting its ability to detect diseases faster via blood and other rapid hospital-based testing.
